Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 17;128(8):1559–1571. doi: 10.1038/s41416-023-02208-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a OS of patients with ALK-mutated tumors versus patients with ALK wildtype tumors at diagnosis (5-year OS, 66% versus 76%). b OS of high-risk patients with tumors harboring ALK mutations at allelic fractions >20% versus ≤ 20% versus ALK wildtype (5-year OS, 28% versus 57% versus 54%). c EFS of high-risk patients with tumors harboring ALK mutations at allelic fractions >20% versus ≤ 20% versus ALK wildtype (5-year EFS, 17% versus 57% versus 33%). d OS of patients with ALK-amplified tumors versus ALK non-amplified tumors at diagnosis (5-year OS, 22% versus 60%). e OS of patients with ALK-amplified versus non-amplified tumors at relapse (5-year OS, 0% versus 57%). f OS of patients with ALK-altered versus ALK-non-altered tumors at relapse (5-year OS, 37% versus 61%). P values were calculated by log-rank and, in case of non-proportional hazards, Gehan-Breslow test. OS, overall survival; y, years; ampl, amplification; AF, allelic fraction.